News | May 03, 2025
Zydus Lifesciences completes 25 years of listing on NSE
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The European regulator will conduct a re-inspection of the facility to verify the compliance
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
ANVIMO will be available in dosages of 240 mg and 480 mg
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Subscribe To Our Newsletter & Stay Updated
